take pressur
despit mdt challeng underli growth outlook solid
fair share challeng notabl mis-step past
month investor right hold management account said mdt
underli growth outlook rel solid despit
long-term target sale growth ep growth exampl
exclud signific increas tax rate management guidanc
would impli ep growth includ neg impact
fx estim fda action paclitaxel take
organ growth would otherwis squar
view today stock reaction partial recognit believ
success execut mgmt outlook drive stock higher
reiter outperform rate price target
modest start expect pipelin drive mgmt
guid call improv perform throughout year
start growth end year catalyst
linq insert monitor insulin pump also announc
unveil soft-tissu robot surgeri system event fall
upcom event catalyst investor brief ada sf
review diabet pipelin host expert dinner ada
along cs pharma team
valuat target price unchang base ebitda
multipl unchang ebitda bil unchang risk
includ key product delay failur progress long-term goal growth
margin potenti new litig regulatori qualiti issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mariu zoican univers toronto rotman school manag may
medtron plc global manufactur provid medic
devic equip area cardiac rhythm manag
vascular intervent structur valvular diseas spinal
disord neuromodul surgic equip diabet
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
mariu zoican univers toronto rotman school manag may
addit detail takeaway
cvg bil mil y/i cc organ vs cse
 heart failur sale bil mil declin organ
arrhythmia manag grew msd driven diagnost af diagnost grew
high-teen driven reveal linq af mid-teen driven continu uptak
arctic front cryoballoon compani report msd declin icd well slight
declin pacemak despit share gain micra tyrx absorb
antibacteri envelop wrap-it trial hit primari endpoint
march
coronari structur heart sale mil mil decreas organ
perform led ldd ww tavr growth in-lin market growth
driven continu strong uptak evolut coronari growth hsd
driven share gain surgic valv
aortic peripher venou sale mil mil increas organ
perform led growth taa driven launch valiant
navion thorac stent graft system thorac endovascular repair dcb busi
declin hsd back paclitaxel uncertainti
europ partial off-set on-going launch japan
manag expect cvg grow flat
mitg bil y/i cc organ vs cse
surgic innov sale bil mil increas organ
advanc stapl advanc energi drove growth quarter despit
shutdown major steril supplier facil manag expect back full
steril capac late advanc surgic hsd driven convers
surgic procedur open minim invas advanc energi grew hsd
advanc stapl msd
respiratori gastrointestin renal sale mil mil increas
organ perform led lsd growth respiratori gi solut
msd growth patient monitor renal solut
manag expect mitg grow growth first
rtg bil mil y/i cc organ vs cse
brain therapi sale mil mil increas organ
quarter compani sold mazor stealth navig robot system
system sold custom enter combin capit implant contract
addit percentag mazor robot case use spine implant rose
double-digit neurovascluar grew high-teen driven double-
digit growth stent retriev flow divert neuro access coil product
neurosurgeri mid-teen driven growth capit equip
pain therapi sale mil mil increas organ
compani continu gain market share despit market recent slowdown
manag estim pain busi achiev market leadership posit
first time two half year
spine sale mil mil declin organ spine
lsd spine combin enabl
technolog revenu reflect neurosurgeri grew
mariu zoican univers toronto rotman school manag may
specialti therapi sale mil mil increas organ
perform driven mid-teen growth transform solut
high-singl digit growth ent
manag expect rtg grow growth first
diabet mil mil y/i cc organ vs
advanc insulin manag growth driven integr cgm on-going
minim system launch ou off-set difficult comparison competit
pressur quarter compani also launch guardian sensor
emea minim pump patient insulin growth solid
result ou sale compani face difficult comparison pump sale
 cgm emerg technolog grew driven ww
demand guardian connect cgm system compani host investor
brief upcom ada confer provid updat pipelin
product launch next month
manag expect diabet grow expect growth
 oper margin bp estim
sale net cog lower expens lower tax lower
partial off-set non-op deliv beat rel estim gross
margin bp y/i bp estim oper
margin bp y/i bp cc basi
manag guid sale growth sale bil growth
expect cc impact transitori headwind steril
shutdown mitg slowdown peripher revenu growth expect
acceler closer back half fx expect
headwind compani guid ep
manag expect bp oper margin
mariu zoican univers toronto rotman school manag may
sale
sale
sale
estimate
ep
sale
sale
mariu zoican univers toronto rotman school manag figur revenu summari actual vs estim
estimate
mariu zoican univers toronto rotman school manag may
chang model
lower sale estim in-lin manag guidanc
beyond lower sale estim base guidanc
paclitaxel impact bottom-lin rais ep in-lin guidanc
leav year estim unchang
figur chang model
target price unchang base ebitda multipl unchang
ebitda bil unchang risk includ key product delay failur
progress long-term goal growth margin potenti new litig regulatori
qualiti issu
mariu zoican univers toronto rotman school manag compani mention price
